Literature DB >> 2644572

Verotoxin receptor glycolipid in human renal tissue.

B Boyd1, C Lingwood.   

Abstract

Infection with verotoxin producing Escherichia coli has been strongly implicated in the etiology of the hemolytic uremic syndrome (HUS). We have previously shown that this toxin specifically binds to a glycolipid receptor-globotriosyl ceramide (Gb3). We have therefore quantitated the level of this glycolipid by HPLC in human renal cortex and medulla as a function of age. We have also measured the binding of verotoxin to Gb3 isolated from each renal tissue sample. Gb3 was a major component of the glycolipid fraction of all renal samples analyzed. The levels were found to be higher in the cortex than medulla, correlating with the clinical incidence of renal lesions in HUS, but reduced in the kidneys of infants as compared to adults. Verotoxin binding was directly proportional to the renal Gb3 content. Thus, human renal tissue is a rich source of the verotoxin receptor glycolipid. However, changes in receptor concentration cannot explain the age-related incidence of HUS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644572     DOI: 10.1159/000185286

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  64 in total

1.  Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide.

Authors:  T Waddell; A Cohen; C A Lingwood
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 2.  Glomerular fibrin deposition and removal.

Authors:  J M Bergstein
Journal:  Pediatr Nephrol       Date:  1990-01       Impact factor: 3.714

Review 3.  New insights into the haemolytic uraemic syndromes.

Authors:  D V Milford; C M Taylor
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

4.  Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin.

Authors:  B Boyd; S Richardson; J Gariepy
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

Review 5.  Anti-virulence strategies to combat bacteria-mediated disease.

Authors:  David A Rasko; Vanessa Sperandio
Journal:  Nat Rev Drug Discov       Date:  2010-01-18       Impact factor: 84.694

Review 6.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

7.  Shigatoxin-1 binding and receptor expression in human kidneys do not change with age.

Authors:  Zuhal Ergonul; Frederic Clayton; Agnes B Fogo; Donald E Kohan
Journal:  Pediatr Nephrol       Date:  2003-02-07       Impact factor: 3.714

8.  Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.

Authors:  L L Cooling; K E Walker; T Gille; T A Koerner
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro.

Authors:  C B Louise; T G Obrig
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

10.  Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro.

Authors:  C B Louise; T G Obrig
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.